You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024

CLINICAL TRIALS PROFILE FOR ELIGARD


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Eligard

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005044 ↗ Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Unknown status National Cancer Institute (NCI) Phase 3 2000-02-01 RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of hormone therapy and radiation therapy in treating patients who have prostate cancer.
NCT00005044 ↗ Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Unknown status Radiation Therapy Oncology Group Phase 3 2000-02-01 RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of hormone therapy and radiation therapy in treating patients who have prostate cancer.
NCT00170157 ↗ Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer Completed Medarex Phase 2 2004-06-01 RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Eligard

Condition Name

Condition Name for Eligard
Intervention Trials
Prostate Cancer 26
Prostate Adenocarcinoma 9
Stage IVB Prostate Cancer AJCC v8 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Eligard
Intervention Trials
Prostatic Neoplasms 47
Adenocarcinoma 13
Carcinoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Eligard

Trials by Country

Trials by Country for Eligard
Location Trials
United States 277
Canada 29
Netherlands 15
Belgium 10
Italy 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Eligard
Location Trials
California 18
Maryland 12
Texas 11
Michigan 9
Illinois 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Eligard

Clinical Trial Phase

Clinical Trial Phase for Eligard
Clinical Trial Phase Trials
Phase 4 6
Phase 3 10
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Eligard
Clinical Trial Phase Trials
Completed 19
Recruiting 16
Active, not recruiting 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Eligard

Sponsor Name

Sponsor Name for Eligard
Sponsor Trials
National Cancer Institute (NCI) 18
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 5
Sanofi 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Eligard
Sponsor Trials
Other 43
Industry 31
NIH 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.